PRO-140: Humanized anti-CCR5 monoclonal antibody anti-HIV agent

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.

Original languageEnglish (US)
Pages (from-to)789-792
Number of pages4
JournalDrugs of the Future
Volume34
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Anti-HIV Agents
Antiviral Agents
Monoclonal Antibodies
HIV
HIV-1
Pharmaceutical Preparations
PRO-140 monoclonal antibody
Therapeutics
In Vitro Techniques
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

PRO-140 : Humanized anti-CCR5 monoclonal antibody anti-HIV agent. / Temesgen, Zelalem.

In: Drugs of the Future, Vol. 34, No. 10, 2009, p. 789-792.

Research output: Contribution to journalArticle

@article{82dbb8462f4a45a687b833c68d520a52,
title = "PRO-140: Humanized anti-CCR5 monoclonal antibody anti-HIV agent",
abstract = "PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.",
author = "Zelalem Temesgen",
year = "2009",
doi = "10.1358/dof.2009.034.10.1426671",
language = "English (US)",
volume = "34",
pages = "789--792",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "10",

}

TY - JOUR

T1 - PRO-140

T2 - Humanized anti-CCR5 monoclonal antibody anti-HIV agent

AU - Temesgen, Zelalem

PY - 2009

Y1 - 2009

N2 - PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.

AB - PRO-140 is a humanized anti-CCR5 monoclonal antibody currently in phase II clinical development for the treatment of HIV. It has exhibited potent in vitro antiviral activity against a broad range of HIV-1 isolates. This antiviral activity has been confirmed in a number of clinical studies involving HIV-infected patients, with no drug-related serious adverse events reported.

UR - http://www.scopus.com/inward/record.url?scp=84930542432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930542432&partnerID=8YFLogxK

U2 - 10.1358/dof.2009.034.10.1426671

DO - 10.1358/dof.2009.034.10.1426671

M3 - Article

AN - SCOPUS:84930542432

VL - 34

SP - 789

EP - 792

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 10

ER -